What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
His main research concerns Internal medicine, Leukemia, Myeloid leukemia, Surgery and Oncology.
His research in Internal medicine intersects with topics in Gastroenterology and Immunology.
His Leukemia study incorporates themes from Myeloid, Pharmacology and Performance status.
His studies in Myeloid leukemia integrate themes in fields like Fms-Like Tyrosine Kinase 3 and Sorafenib.
His work investigates the relationship between Surgery and topics such as Myelodysplastic syndromes that intersect with problems in Decitabine and Azacitidine.
His research investigates the link between Oncology and topics such as NPM1 that cross with problems in IDH2.
His most cited work include:
- Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. (432 citations)
- Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. (371 citations)
- Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome (334 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Oncology, Myeloid leukemia, Gastroenterology and Surgery.
His research links Immunology with Internal medicine.
The concepts of his Oncology study are interwoven with issues in Cancer, Imatinib, Dasatinib and Decitabine.
His Myeloid leukemia study combines topics in areas such as Myeloid, Myelodysplastic syndromes, Bone marrow and Disease.
Farhad Ravandi combines subjects such as Refractory, Vincristine, Neutropenia, Minimal residual disease and Acute lymphocytic leukemia with his study of Gastroenterology.
His Leukemia research includes themes of Clinical trial, Pathology and Pharmacology.
He most often published in these fields:
- Internal medicine (77.14%)
- Oncology (41.00%)
- Myeloid leukemia (36.08%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (77.14%)
- Oncology (41.00%)
- Myeloid leukemia (36.08%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Oncology, Myeloid leukemia, Cancer research and Leukemia.
Farhad Ravandi conducts interdisciplinary study in the fields of Internal medicine and In patient through his research.
His Oncology research is multidisciplinary, relying on both Blinatumomab, Lymphoblastic Leukemia, Ponatinib and Decitabine.
Farhad Ravandi has included themes like Refractory, Gastroenterology, Disease, Bone marrow and Cohort in his Myeloid leukemia study.
His work carried out in the field of Gastroenterology brings together such families of science as Adverse effect and Neutropenia.
His Leukemia research incorporates themes from Myeloid and Cancer.
Between 2018 and 2021, his most popular works were:
- Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet (134 citations)
- Acute myeloid leukemia, version 3.2019 (90 citations)
- The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia (82 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
Farhad Ravandi focuses on Internal medicine, Myeloid leukemia, Oncology, Venetoclax and Leukemia.
His work in Internal medicine addresses issues such as Decitabine, which are connected to fields such as Clinical endpoint.
His Myeloid leukemia research includes themes of Gastroenterology, Bone marrow and Cohort.
His Oncology research is multidisciplinary, incorporating elements of Phases of clinical research, Azacitidine, Cyclophosphamide, Blinatumomab and Acute lymphocytic leukemia.
His Venetoclax research also works with subjects such as
- Combination therapy which intersects with area such as Ponatinib,
- Neutropenia which is related to area like Cytokine release syndrome.
His Leukemia research includes elements of Myeloid, Cancer and Disease.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
